![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 13, 2009 5:52:56 PM
Recent SONN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/19/2024 09:28:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/19/2024 09:27:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 12:50:25 PM
- Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 08/19/2024 12:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 12:45:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:41:20 PM
- Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/14/2024 12:35:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/09/2024 09:28:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 12:36:15 PM
- Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study • GlobeNewswire Inc. • 07/24/2024 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/15/2024 09:05:56 PM
- Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds • GlobeNewswire Inc. • 06/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:15:34 PM
- Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain • GlobeNewswire Inc. • 06/13/2024 12:00:00 PM
- Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 11:35:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 01:25:20 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/16/2024 08:16:44 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/15/2024 08:06:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 09:25:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 09:07:54 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM